Loading...
XSHE000403
Market cap2.13bUSD
Jan 16, Last price  
21.51CNY
1D
0.51%
1Q
-3.63%
Jan 2017
28.04%
Name

Pacific Shuanglin Bio-pharmacy Co Ltd

Chart & Performance

D1W1MN
XSHE:000403 chart
P/E
25.55
P/S
6.71
EPS
0.84
Div Yield, %
0.37%
Shrs. gr., 5y
6.48%
Rev. gr., 5y
22.05%
Revenues
2.33b
-3.18%
669,811,344742,951,367674,900,344645,031,389578,800,850465,910,788545,673,096461,068,440469,824,199477,715,809489,495,707500,269,283567,436,434685,378,117859,843,304915,656,5681,049,937,6911,971,734,3152,405,188,4252,328,723,279
Net income
612m
+4.25%
00034,608,101202,007,7462,328,37629,226,74040,706,45932,573,52270,280,260122,516,59577,563,03753,895,94515,244,65279,982,796160,448,038185,965,308391,063,978587,131,491612,111,043
CFO
679m
+29.53%
049,058,568095,029,80474,902,010111,864,9209,878,186130,137,466123,244,98591,006,89977,039,22170,310,54062,487,3610116,634,762190,843,307194,839,665408,218,063524,218,863679,006,331
Dividend
Jun 28, 20240.19993 CNY/sh
Earnings
May 21, 2025

Profile

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.
URL
http://www.plbio.cn/
IPO date
Jun 28, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,328,723
-3.18%
2,405,188
21.98%
Cost of revenue
1,521,322
1,665,542
Unusual Expense (Income)
NOPBT
807,402
739,647
NOPBT Margin
34.67%
30.75%
Operating Taxes
76,636
72,702
Tax Rate
9.49%
9.83%
NOPAT
730,765
666,945
Net income
612,111
4.25%
587,131
50.14%
Dividends
(58,611)
(41,046)
Dividend yield
0.29%
0.25%
Proceeds from repurchase of equity
(24,234)
BB yield
0.12%
Debt
Debt current
250,571
290,879
Long-term debt
239,034
112,074
Deferred revenue
35,603
40,083
Other long-term liabilities
9,000
9,000
Net debt
(1,363,082)
(1,620,641)
Cash flow
Cash from operating activities
679,006
524,219
CAPEX
(377,268)
Cash from investing activities
(366,838)
Cash from financing activities
38,237
148,460
FCF
456,069
345,961
Balance
Cash
1,852,687
1,423,232
Long term investments
1
600,362
Excess cash
1,736,251
1,903,335
Stockholders' equity
2,568,660
2,149,981
Invested Capital
6,198,344
5,296,409
ROIC
12.71%
13.11%
ROCE
10.14%
10.23%
EV
Common stock shares outstanding
728,637
730,990
Price
27.28
19.86%
22.76
-18.80%
Market cap
19,877,207
19.47%
16,637,342
-16.07%
EV
18,514,125
15,016,700
EBITDA
952,868
866,032
EV/EBITDA
19.43
17.34
Interest
8,405
12,026
Interest/NOPBT
1.04%
1.63%